Author:
Passarelli Anna,Pisano Carmela,Coppola Elisabetta,Ventriglia Jole,Cecere Sabrina Chiara,Di Napoli Marilena,Carideo Luciano,Lastoria Secondo,Pignata Sandro
Abstract
Cervical cancer (CC) is the second most commonly diagnosed cancer and the third leading cause of cancer death among females. The options of treatment for recurrent/advanced CC are limited and patients experiencing recurrence after first line platinum-based chemotherapy have a poor prognosis. In this context, immune checkpoint inhibitors (ICI)s antagonizing PD-1 and programmed death-ligand 1 (PD-L1) have profoundly changed the treatment scenario and outcomes in CC in the first or subsequent lines both as monotherapies or in combination with chemotherapy or other ICIs. Herein, we report the clinical case of a 74-year-old woman with metastatic CC with negative tumor PD-L1 expression who having disease progression after first-line of systemic treatment with platinum, thus undergoing to anti-PD-1 namely cemiplimab. The patient achieved a surprising, fast and complete metabolic response to cemiplimab immediately discontinued after only two cycles due to the onset of rare and severe immune-related adverse events (irAE)s such cardiovascular toxicity and hypertransaminasemia. Despite this, thirteen months later, the patient remains disease-free despite cemiplimab was withdrawn.
Subject
Immunology,Immunology and Allergy
Reference28 articles.
1. Cancer statistics, 2021;Siegel;CA: Cancer J Clin,2021
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors;Arbyn;Cochrane Database Systematic Rev,2018
3. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study;Moore;J Clin Oncol,2004
4. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study;Long;J Clin Oncol,2005
5. Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study;Monk;J Clin Oncol,2009
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Carboplatin/cemiplimab;Reactions Weekly;2024-01-20